U.S. markets open in 3 minutes
  • S&P Futures

    4,079.75
    -2.00 (-0.05%)
     
  • Dow Futures

    34,009.00
    -420.00 (-1.22%)
     
  • Nasdaq Futures

    11,825.25
    -237.50 (-1.97%)
     
  • Russell 2000 Futures

    1,853.70
    -30.00 (-1.59%)
     
  • Crude Oil

    80.81
    -0.41 (-0.50%)
     
  • Gold

    1,799.00
    -16.20 (-0.89%)
     
  • Silver

    22.68
    -0.16 (-0.68%)
     
  • EUR/USD

    1.0485
    -0.0043 (-0.41%)
     
  • 10-Yr Bond

    3.6050
    +0.0760 (+2.15%)
     
  • Vix

    20.78
    +0.20 (+0.97%)
     
  • GBP/USD

    1.2212
    -0.0044 (-0.36%)
     
  • USD/JPY

    135.3030
    -0.0030 (-0.00%)
     
  • BTC-USD

    16,918.42
    -135.07 (-0.79%)
     
  • CMC Crypto 200

    401.31
    -4.84 (-1.19%)
     
  • FTSE 100

    7,528.34
    -30.15 (-0.40%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

One Analyst Is Bullish On Medtronic, Another Is Not Post Q1 Earnings

  • Citi says that Medtronic plc (NYSE: MDT) delivered better-than-expected FY1Q23 results, reiterating FY23 guidance despite the ongoing litany of pressures impacting Medtech.

  • The analyst notes a shift in tone, with many of these headwinds still present but improving, including the availability of chips; patient volumes returning to pre-pandemic levels.

  • Citi maintains the Buy rating on MDT.

  • Related: Medtronic Q1 Earnings Within Expectation, Sees Higher Currency Headwind On FY23 Sales.

  • But Raymond James downgraded Medtronic to Market Perform from an Outperform rating.

  • The analyst notes that the valuation has been their core thesis this year, and this factor still holds, but the implied F2H23 ramp lowers confidence.

  • According to the analyst, supply chain dynamics have disrupted MDT’s growth more than peers, and they think MDT will take longer to regain momentum.

  • Raymond James is increasingly concerned that a higher level of investment is needed to drive a mid-single-digit revenue growth profile.

  • Price Action: MDT shares are down 0.91% at $89.41 on the last check Wednesday.

Latest Ratings for MDT

Date

Firm

Action

From

To

Feb 2022

Credit Suisse

Maintains

Outperform

Feb 2022

Needham

Maintains

Buy

Feb 2022

Raymond James

Maintains

Outperform

View More Analyst Ratings for MDT

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.